Evidence map›Paper›PMID 37550022›Full record

ArticleBMJ open2023

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.

Oghenekome Gbinigie, Emma Ogburn, Julie Allen, Jienchi Dorward, Melissa Dobson, Tracie-Ann Madden, Ly-Mee Yu, David M Lowe, Najib Rahman, Stavros Petrou and 38 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
12.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.International journal of molecular sciences · 2024
    Review
  14. Article
  15. Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 16 institutions in 3 countries.

Oghenekome GbinigieNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID 0000-0002-2963-4491
Emma OgburnNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Julie AllenNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Jienchi DorwardNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID 0000-0001-6072-1430
Melissa DobsonNuffield Department of Medicine, Oxford Respiratory Trials Unit, Oxford, UK.
Tracie-Ann MaddenCentre for Trials Research, Cardiff University, Cardiff, UK.
Ly-Mee YuNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
David M LoweUniversity College London, Institute of Immunity and Transplantation, London, UK.
Najib RahmanNuffield Department of Medicine, Oxford Respiratory Trials Unit, Oxford, UK.
Stavros PetrouNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Duncan RichardsNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.
Kerenza HoodCentre for Trials Research, Cardiff University, Cardiff, UK.
Mahendra PatelNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Benjamin R SavilleBerry Consultants, Austin, Texas, USA.
Joe MarionBerry Consultants, Austin, Texas, USA.
Jane HolmesNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
May Ee PngNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID 0000-0001-5876-9363
Gail HaywardNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID 0000-0003-0852-627X
Mark LownPrimary Care Research Centre, University of Southampton, Southampton, UK.ORCID 0000-0001-8309-568X
Victoria HarrisNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Bhautesh JaniGeneral Practice and Primary Care, School of Health and Wellbeing, MVLS, University of Glasgow, Glasgow, UK.
Nigel HartSchool of Medicine, Dentistry and Biomedical Sciences - Centre for Public Health, Queen's University Belfast, Belfast, UK.
Saye KhooDepartment of Pharmacology, University of Liverpool, Liverpool, UK.
Heather RutterNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Jem ChalkNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Joseph F StandingInfection Inflammation and Immunology, UCL Great Ormond Street Institute of Child Health Population Policy and Practice, London, UK.
Judith BreuerInfection Inflammation and Immunology, UCL Great Ormond Street Institute of Child Health Population Policy and Practice, London, UK.
Layla LavalleeNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Elizabeth HadleyNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Lucy CuretonNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Magdalena BenysekNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Monique I AnderssonDepartment of Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID 0000-0003-0619-1074
Nick FrancisPrimary Care Research Centre, University of Southampton, Southampton, UK.ORCID 0000-0001-8939-7312
Nicholas P B ThomasWindrush Medical Practice, Witney, UK.
Philip EvansFaculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Oliver van HeckeNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Mona KoshkoueiNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Maria CoatesNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Sarah BarrettNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Clare BatemanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Jennifer DaviesNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Ivy Raymundo-WoodNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Andrew UstianowskiRegional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK.
Jonathan Nguyen-Van-TamLifespan and Population Health Unit, University of Nottingham School of Medicine, Nottingham, UK.
Andrew Carson-StevensCentre for Trials Research, Cardiff University, Cardiff, UK.
Richard HobbsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Paul LittlePrimary Care Research Centre, University of Southampton, Southampton, UK.ORCID 0000-0003-3664-1873
Christopher C ButlerNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK christopher.butler@phc.ox.ac.uk.ORCID 0000-0002-0102-3453
University of Oxford · GBCardiff University · GBNIHR Southampton Biomedical Research Centre · GBBerry & Associates (United States) · USUniversity College London · GBCentre for the AIDS Programme of Research in South Africa · ZAGreat Ormond Street Hospital · GBNIHR Research Delivery Network · GBNorth Manchester General Hospital · GBNuffield Orthopaedic Centre · GBOxford University Hospitals NHS Trust · GBQueen's University Belfast · GBUniversity of Exeter · GBUniversity of Glasgow · GBUniversity of Liverpool · GBUniversity of Nottingham · GB

Funding

Department of Health NF-SI-0616-10103Medical Research Council MR/M008665/1Medical Research Council MR/W015560/1Wellcome TrustWellcome Trust 216421/Z/19/Z
6 · The paper itself

Abstract

introductionThere is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. METHODS AND ANALYSIS: PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid). ELIGIBILITY CRITERIA: community-dwelling within 5 days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18-49 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial. ETHICS AND DISSEMINATION: Ethical approval granted by South Central-Berkshire REC number: 21/SC/0393; IRAS project ID: 1004274. Results will be presented to policymakers and at conferences, and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: ISRCTN30448031; EudraCT number: 2021-005748-31.

Indexed as

COVID-19Adaptive Clinical Trials as TopicAgedAntiviral AgentsDrug CombinationsHumansLactamsLeucineMiddle AgedNitrilesProlineProspective StudiesRandomized Controlled Trials as TopicRitonavirSARS-CoV-2Treatment OutcomeAntiviral AgentsDrug CombinationsLactamsLeucinenirmatrelvir and ritonavir drug combinationNitrilesProlineRitonavirclinical trialsCOVID-19primary caretherapeuticsvirology

Identifiers

PMID37550022
PMCPMC10407406
OpenAlexW4385622189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.